Liver disease, a major global health burden, ranges from mild dysfunction to severe conditions like cirrhosis and hepatocellular carcinoma (HCC), the fifth most common cancer. Accurate diagnosis of liver lesions-distinguishing benign from malignant-is vital for treatment planning. Conventional imaging (ultrasound, CT, MRI) has limitations in sensitivity and detecting small metastases. PET/CT combines metabolic and anatomical data but struggles with small lesions and cirrhotic livers.
18F-FDG PET/MRI with contrast-enhanced MRI may improve diagnostic accuracy, but its clinical benefits remain uncertain. Further research is needed to evaluate its performance, impact on patient outcomes, and cost-effectiveness in liver disease management.
Age ≥18 years;
Patients with suspected liver metastases or hepatic lesions,
Ability to undergo 18F-FDG PET/MRI examination;
Willingness to comply with study protocols.
Patients with a history of allergic reactions to MRI contrast agents;
Pregnant or lactating women;
Patients with severe comorbidities, including: Cardiac disease，Renal failure，or Hepatic failure (Child-Pugh C);
Patients unable to cooperate with PET/MRI procedures.
All patients who meet the inclusion and exclusion criteria and are willing to follow the research process.
Cohort
Prospective
Not listed
Metabolic parameters
For all liver lesions, the maximum standardized uptake value (SUVmax) will be calculated.
MRI enhancement pattern
The MRI protocol will specifically evaluate the dynamic contrast-enhanced patterns of lesions, including their enhancement characteristics during the arterial phase, portal venous phase, and delayed phase.
Normal liver SUVmax
Calculate the maximum standardized uptake value (SUVmax) of normal liver tissue surrounding the lesion.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
